Devyser Diagnostics AB (DVYSR)

Currency in SEK
148.00
-2.80(-1.86%)
Closed·
DVYSR Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
DVYSR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
146.40153.20
52 wk Range
83.30155.00
Key Statistics
Prev. Close
150.8
Open
153.2
Day's Range
146.4-153.2
52 wk Range
83.3-155
Volume
14.54K
Average Volume (3m)
23.18K
1-Year Change
40.93%
Book Value / Share
20.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DVYSR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
164.44
Upside
+11.11%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Devyser Diagnostics AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Devyser Diagnostics AB Company Profile

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.

Employees
118
Market
Sweden

Devyser Diagnostics AB Earnings Call Summary for Q2/2025

  • Revenue reached SEK 67.4M, up 27% YoY, beating forecast of SEK 61.93M. Stock price rose 8.03% post-announcement.
  • US market growth of 200% QoQ. Company targets 30% annual organic growth and 80% gross margin.
  • Three new products launched. FDA approval process ongoing for transplantation products.
  • Acting CEO Fredrik Dahl: 'We are turning the company around on a path to profitability.'
  • Challenges include softer Asia Pacific sales and potential regulatory hurdles in FDA approval process.
Last Updated: 22/07/2025, 09:10
Read Full Transcript

Compare DVYSR to Peers and Sector

Metrics to compare
DVYSR
Peers
Sector
Relationship
P/E Ratio
−54.8x5.0x−0.5x
PEG Ratio
−3.090.020.00
Price/Book
7.4x3.2x2.6x
Price / LTM Sales
10.6x9.0x3.3x
Upside (Analyst Target)
11.1%11.6%43.4%
Fair Value Upside
Unlock24.7%7.1%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 164.44
(+11.11% Upside)

Earnings

Latest Release
Jul 22, 2025
EPS / Forecast
0.20 / -0.132
Revenue / Forecast
67.40M / 61.93M
EPS Revisions
Last 90 days

DVYSR Income Statement

FAQ

What Stock Exchange Does Devyser Diagnostics AB Trade On?

Devyser Diagnostics AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Devyser Diagnostics AB?

The stock symbol for Devyser Diagnostics AB is "DVYSR."

What Is the Devyser Diagnostics AB Market Cap?

As of today, Devyser Diagnostics AB market cap is 2.46B.

What Is Devyser Diagnostics AB's Earnings Per Share (TTM)?

The Devyser Diagnostics AB EPS (TTM) is -2.76.

When Is the Next Devyser Diagnostics AB Earnings Date?

Devyser Diagnostics AB will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is DVYSR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Devyser Diagnostics AB Stock Split?

Devyser Diagnostics AB has split 0 times.

How Many Employees Does Devyser Diagnostics AB Have?

Devyser Diagnostics AB has 118 employees.

What is the current trading status of Devyser Diagnostics AB (DVYSR)?

As of 08 Aug 2025, Devyser Diagnostics AB (DVYSR) is trading at a price of 148.00, with a previous close of 150.80. The stock has fluctuated within a day range of 146.40 to 153.20, while its 52-week range spans from 83.30 to 155.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.